Table 1 Patient and transplant characteristics in the whole cohort and stratified by induction cycles.

From: Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMT

 

Number of induction cycles

p-value

Characteristic

Total N = 2444

1 N = 2038

2 N = 296

≥ 3 N = 110

 

Median age at transplant, years (IQR)

40 (18–73)

41 (18–73)

38 (18–73)

36 (18–70)

0.067

Gender, n (%)

    

0.15

 Female

1015 (42)

862 (42)

107 (36)

46 (42)

 

 Male

1428 (58)

1176 (58)

188 (64)

64 (58)

 

 Missing

1

0

1

0

 

Karnofsky performance status, n (%)

    

0.14

 ≥90

1346 (70)

1134 (71)

146 (64)

66 (72)

 

 < 90

577 (30)

470 (29)

81 (36)

26 (28)

 

 Missing

521

434

69

18

 

Type of ALL, n (%)

    

<0.001

 T-cell

513 (21)

392 (19)

82 (28)

39 (36)

 

 B-cell Ph positive

948 (39)

845 (41)

82 (28)

21 (19)

 

 B-cell Ph negative

672 (27)

544 (27)

88 (29)

40 (36)

 

 B-cell Ph unknown

311 (13)

257 (13)

44 (15)

10 (9)

 

Year of transplant, median (IQR)

2013 (2007–2018)

2013 (2008– 2018)

2011 (2006– 2017)

2017 (2009– 2019)

<0.001

Conditioning intensity, n (%)

    

0.9

 MAC

2007 (82)

1670 (82)

245 (83)

92 (84)

 

 RIC

434 (18)

366 (18)

50 (17)

18 (16)

 

 Missing

3

2

1

0

 

Type of conditioning, n (%)

    

0.72

 Chemotherapy-based

635 (26)

528 (26)

81 (27)

26 (24)

 

 TBI-based

1806 (74)

1508 (74)

214 (73)

84 (76)

 

 Missing

3

2

1

0

 

Donor-recipient CMV serostatus, n (%)

    

0.47

 Positive/Positive

812 (34)

674 (34)

109 (38)

29 (27)

 

 Positive/Negative

285 (12)

237 (12)

31 (11)

17 (16)

 

 Negative/Positive

490 (20)

406 (20)

58 (20)

26 (24)

 

 Negative/Negative

812 (34)

683 (34)

92 (32)

37 (34)

 

 Missing

45

38

6

1

 

Female donor to male recipient, n (%)

446 (18)

369 (18)

64 (22)

13 (12)

0.059

Stem cell source, n (%)

    

0.032

 Bone marrow

710 (29)

610 (30)

79 (27)

21 (19)

 

 Peripheral blood

1734 (71)

1428 (70)

217 (73)

89 (81)

 

Type of donor, n (%)

    

0.47

 Matched sibling

1035 (47)

883 (48)

115 (46)

37 (38)

 

 Matched unrelated

730 (33)

604 (33)

84 (34)

42 (43)

 

 Haploidentical

172 (8)

141 (8)

23 (9)

8 (8)

 

 Mismatched unrelated

244 (11)

205 (11)

28 (11)

11 (11)

 

 Missing

263

204

45

11

 

In vivo T-cell depletion, n (%)

1089 (45)

896 (44)

138 (48)

55 (50)

0.27

GVHD prophylaxis, n (%)

    

0.45

 CNI + MTX

1460 (60)

1231 (60)

163 (55)

66 (60)

 

 PT-Cy based

204 (8)

172 (8)

21 (7)

11 (10)

 

 Other

780 (32)

635 (32)

112 (38)

33 (30)

 
  1. ALL acute lymphoblastic leukemia, Ph Philadelphia chromosome, MAC myeloablative conditioning, RIC reduced intensity conditioning, TBI total body irradiation, CMV cytomegalovirus, GVHD graft-versus-host-disease, CNI calcineurin inhibitor, MTX methotrexate, PT-Cy posttransplant cyclophosphamide
Back to article page